Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CARsgen's Claudin18.2 CAR T-Cell Candidate Granted US RMAT Designation

publication date: Jan 14, 2022

CARsgen Therapeutics, a Shanghai CAR-T-company, was granted Regenerative Medicine Advanced Therapy (RMAT) designation in the US for CT041, an autologous CAR T-cell product. CT041 is being developed for advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) with a Claudin18.2-positive tumor. The RMAT designation means CT041 has the benefits of Fast Track and Breakthrough Therapy designations. CT041 is the only CLDN18.2-targeted CAR T-cell candidate currently with IND approvals in the US, China and Canada. More details....

Stock Symbol: (HK: 2171)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.